Skip to main
BSX
BSX logo

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 43 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 16%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific's total sales for the fourth quarter reached $4.561 billion, reflecting a robust year-over-year growth of 19.5%, significantly exceeding projections. The Cardiovascular business showed particularly strong performance with a year-over-year increase of 27%, contributing 65% of fourth-quarter sales, thus highlighting the substantial demand for the company's diverse portfolio of less invasive medical devices. Furthermore, the positive outlook is bolstered by expectations of continued operating margin expansion, driven by higher gross margins, strategic reinvestment in R&D, and the potential for greater operating leverage from faster revenue growth.

Bears say

The financial outlook for Boston Scientific indicates challenges ahead, with a projected decline in gross margins for 2024 by approximately 40 basis points year-over-year, primarily due to limitations from the capital sale energy generator system. Additionally, potential risks encompass weaker-than-expected sales in key segments such as electrophysiology and structural heart, alongside increased competition and operating margin contraction that could hinder revenue growth. The company's revenue projections suggest flat growth in the first quarter of 2025, reflecting significant headwinds including market share losses and regulatory hurdles, which contribute to the negative outlook on its stock.

Boston Scientific (BSX) has been analyzed by 43 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 16% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 43 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Jul 6, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.